Now Available:
Watch video podcasts of the 2008 EULAR press conferences

CME Opportunity:

Arthritis: FDA Warns of Histoplasmosis, Invasive Fungal Infections in Patients Taking TNF Inhibitors
The US Food and Drug Administration has issued a "MedWatch" warning about the risk of histoplasmosis and other invasive fungal infections in patients taking TNF blockers...

Arthritis: ACR Research and Education Foundation Grants Point to New Arthritis Research
New REF grants target RA immunotherapy, inflammation, bone erosions, PAD inhibition...

Consumer News: FDA Posts List of Potential Problem Drugs
The FDA has posted a list of prescription drugs that are under investigation for potential safety problems...

BioPharm Business: Can-Fite Reports that Seikagaku Corp, Exclusive Licensee of CF101 in Japan, is to Initiate Phase I Trial in Japan to Treat RA; Can-Fite to Receive $1 Million USD
CF101, Can-Fite's lead compound, is an oral drug that has been successfully used in animal models and human phase IIa RA trials to test the concept of targeting A(3)AR for the treatment of inflammatory diseases...

Click here to remove your e-mail address from our mailing list. For questions and comments regarding this newsletter please contact .